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Abstract
Background Drugs with anticholinergic effects are asso-
ciated with adverse events such as delirium and falls as
well as cognitive decline and loss of independence.
Objective The aim of the study was to evaluate the
association between anticholinergic burden and both cog-
nitive and functional status, according to the hypothesis
that the cumulative anticholinergic burden, as measured by
the Anticholinergic Cognitive Burden (ACB) Scale and
Anticholinergic Risk Scale (ARS), increases the risk of
cognitive decline and impairs activities of daily living.
Methods This cross-sectional, prospective study (3-month
telephone follow-up) was conducted in 66 Italian internal
medicine and geriatric wards participating in the Registry of
Polytherapies SIMI (Societa` Italiana di Medicina Interna)
(REPOSI) study during 2010. The sample included 1,380
inpatients aged 65 years or older. Cognitive status was rated
with the Short Blessed Test (SBT) and physical function
with the Barthel Index. Each patient’s anticholinergic bur-
den was evaluated using the ACB and ARS scores.
Results The mean SBT score for patients treated with
anticholinergic drugs was higher than that for patients
receiving no anticholinergic medications as also indicated
by the ACB scale, even after adjustment for age, sex,
education, stroke and transient ischaemic attack [9.2 (95 %
CI 8.6–9.9) vs. 8.5 (95 % CI 7.8–9.2); p = 0.05]. There
was a dose–response relationship between total ACB score
and cognitive impairment. Patients identified by the ARS
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had more severe cognitive and physical impairment than
patients identified by the ACB scale, and the dose–response
relationship between this score and ability to perform
activities of daily living was clear. No correlation was
found with length of hospital stay.
Conclusions Drugs with anticholinergic properties iden-
tified by the ACB scale and ARS are associated with worse
cognitive and functional performance in elderly patients.
The ACB scale might permit a rapid identification of drugs
potentially associated with cognitive impairment in a dose–
response pattern, but the ARS is better at rating activities of
daily living.
1 Introduction
Polypharmacy is very common among older adults and may
often be needed to improve symptoms, disease-related
problems and quality of life [1–3]. However, it may also be
a major risk for inappropriate prescribing, poor adherence
to therapies, adverse drug events and other adverse health
outcomes [4–8]. Elderly patients are at particularly high risk
because of multiple illnesses, and there is ample evidence
that drugs with anticholinergic properties are especially
likely to cause adverse events [9–21] leading to cognitive
impairment, delirium, falls and loss of independence [22,
23]. Amongst the oldest subjects, the use of anticholinergic
drugs has also been associated with impaired physical
performance and functional status [24]. Anticholinergic
drugs may affect the brain by blocking the neurotransmitter
acetylcholine, and older people are more susceptible to
these effects because of several age-related changes, such as
a decrease in cholinergic neurons or receptors in the brain, a
reduction in hepatic and renal clearance of drugs, and an
increase in blood–brain barrier permeability, particularly
during an acute physical illness [10, 25–27]. Reducing the
use of anticholinergic medications is one predictable way of
modifying the risk of this morbidity in elderly people [28].
The Anticholinergic Cognitive Burden (ACB) Scale [29]
and the Anticholinergic Risk Scale (ARS) [28] are two
scoring systems that rank anticholinergic medications and
were developed to predict the risk of anticholinergic adverse
effects in older patients. We examined data from the Registry
of Polytherapies SIMI (Societa` Italiana di Medicina Interna)
(REPOSI) study, which involved a network of internal
medicine and geriatric wards created to collect information
on elderly inpatients with multiple diseases and undergoing
various therapies (see Appendix S1 for information on the
members of the REPOSI Study [Online Resource 1]). Our
aim was to assess the association between anticholinergic
burden and both cognitive and functional status, according to
the hypothesis that the cumulative anticholinergic burden
increases the risk of cognitive decline and impairs activities
of daily living in elderly patients admitted to internal medi-
cine and geriatric wards.
2 Methods
2.1 Data Collection
The REPOSI study is a collaborative, independent, voluntary
effort by the Italian Society of Internal Medicine (SIMI) and the
Mario Negri Institute for Pharmacological Research, and has
been described elsewhere in detail [30–35]. It was set up in
2008 to create a network of internal medicine and geriatric
wards in order to collect national information on hospitalized
elderly patients with multiple diseases often receiving poly-
therapy. Participation was voluntary and all patients provided
signed informed consent. Data collection complied fully with
Italian law on personal data protection. Under the applicable
legal principles on patients’ registries, the study did not require
ethical committee approval. The attending physicians com-
pleted a standardized web-based Case Report Form, which
included information on the following: diagnosis at hospital
admission; sociodemographic details; drug treatments at hos-
pital admission, in-hospital stay and discharge; some labora-
tory parameters; comorbidity according to the Cumulative
Illness Rating Scale (CIRS) [36]; performance in basic activ-
ities of daily living according to the Barthel Index (BI) [37];
cognitive impairment according to the Short Blessed Test
(SBT) [38]; presence of depression according to the Geriatric
Depression Scale [39]; clinical events during hospitalization;
and outcomes. Patients were followed up 3 months after dis-
charge, and data were collected on any new diagnoses, new
hospital admission, drug regimens, adverse drug events and
ability to perform activities of daily living (according to the BI).
2.2 Exposure to Anticholinergic Drugs
Several drugs have anticholinergic activity, and different
scales have been proposed to classify medications
according to their anticholinergic effects [28, 29, 40]. The
two most recent scales assessing the risk of anticholinergic
effects in a clinical setting differ in the number of drugs
included, and some drugs are classified differently. The
ACB scale (Table 1) [29] is as a practical tool to identify
the severity of any anticholinergic negative effect on
cognition. Drugs with possible anticholinergic effects are
defined as those with serum anticholinergic activity or
in vitro affinity for muscarinic receptors but no known
clinically relevant cognitive effects (ACB score 1). Drugs
with established, clinically relevant cognitive effects are
considered definitely anticholinergic (ACB score 2 or 3).
The second scale, the ARS (Table 1) [28], estimates the
extent to which an individual patient may be at risk of
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anticholinergic adverse effects that can lead to cognitive
dysfunction, delirium and peripheral anticholinergic adverse
effects such as dry mouth, dry eyes and constipation. In the
ARS, medications are divided according to their anticho-
linergic potential on a 3-point scale: drugs with moderate
anticholinergic potential (ARS score 1), strong potential
(ARS score 2) and very strong potential (ARS score 3).
For the purposes of this study, we calculated the drug-
related anticholinergic burden for each patient, using the
sum of the points for each anticholinergic medication dis-
pensed at hospital admission, according to both scales.
2.3 Cognitive Impairment
The SBT was conducted within 2 days of hospital admission.
In cases where patients were considered unstable (such as in
those with delirium), the SBT was conducted after stabiliza-
tion. This is a six-item orientation memory concentration test
validated as a measure of cognitive impairment that can dis-
tinguish mild, moderate and severe cognitive deficits, with the
following cut points: normal cognition (scores of 0–4),
questionable impairment (scores of 5–9) and impairment
consistent with dementia (scores of 10–28) [41]. To avoid
ceiling effects in the SBT scale, we excluded patients with a
score of C25, with the aim of excluding any patients with a
diagnosis of dementia, in which the cognitive effects of anti-
cholinergic medication might be reduced and hard to detect.
Among patients with SBT scores of 0–24, we excluded 13
because they had a diagnosis of dementia or were being treated
with anticholinesterase agents or memantine.
2.4 Ability in Basic Activities of Daily Living
The BI is used to assess ability in basic activities of daily
living. It was performance based and was done within
2 days of hospital admission or when patients were con-
sidered stable. It considers ten variables and yields scores
of 0–100. A high score is associated with a greater like-
lihood of being able to live at home with a good degree of
independence after discharge from hospital. Subjects can
be divided into five levels of dependence: total (scores of
0–24), severe (scores of 25–49), moderate (scores of
50–74), mild (scores of 75–90) and minimal impairment
(scores of 91–100). In order to avoid ceiling effects, we
excluded any patients with a score lower than 15, so as to
exclude most patients with the highest degree of physical
impairment, in whom it might be more difficult to detect
any potential effects of anticholinergic drugs on the basic
activities of daily living.
2.5 Statistical Analysis
Analysis of variance was used to study the relationship
between drug-related anticholinergic burden and cognitive
performance as assessed using the SBT or BI, both in uni-
variate and multivariate models. Multivariate analyses of the
association between SBT and anticholinergic drug use were
adjusted for the known risk factors such as age, sex, educa-
tion, and history of stroke or transient ischaemic attack
(TIA) and number of non-anticholinergic drugs as possible
confounders, while analyses for the association between
Table 1 Anticholinergic Cognitive Burden (ACB) Scale [29] and Anticholinergic Risk Scale (ARS) [28] scores
Score Drug
ACB scale
1 Alimemazine, alverine, alprazolam, atenolol, brompheniramine maleate, bupropion, captopril, chlortalidone, cimetidine, clorazepate,
codeine, colchicine, diazepam, digoxin, dipyridamol, disopyramide, fentanyl, furosemide, fluvoxamine, haloperidol, hydralazine,
hydrocortisone, isosorbide, loperamide, metoprolol, morphine, nifedipine, prednisone, quinidine, ranitidine, risperidone, theophylline,
trazodone, triamterene, warfarin
2 Amantadine, belladonna alkaloids, carbamazepine, cyclobenzaprine, cyproheptadine, empracet, loxapine, meperidine,
methotrimeprazine, molindone, oxcarbazepine, pethidine, pimozide
3 Amitriptyline, amoxapine, atropine, benztropine, brompheniramine, carbinoxamine, chlorpheniramine, chlorpromazine, clemastine,
clomipramine, clozapine, darifenacin, desipramine, dicyclomine, dimenhydrinate, diphenhydramine, doxepin, flavoxate, hydroxyzine,
hyoscyamine, imipramine, meclizine, nortriptyline, olanzapine, orphenadrine, oxybutynin, paroxetine, perphenazine, procyclidine,
promazine, promethazine, propantheline, pyrilamine, quetiapine, scopolamine, thioridazine, tolterodine, trifluoperazine,
trihexyphenidyl, trimipramine
ARS
1 Carbidopa-levodopa, entacapone, haloperidol, methocarbamol, metoclopramide, mirtazapine, paroxetine, pramipexole, quetiapine,
ranitidine, risperidone, selegiline, trazodone, ziprasidone
2 Amantadine, baclofene, cetirizine, cimetidine, clozapine, cyclobenzaprine, desipramine, loperamide, loratadine, nortriptyline,
olanzapine, prochlorperazine, pseudoephedrine, tolterodine, triprolidine
3 Amitriptyline, atropine, benztropine, carisoprodol, chlorpheniramine, chlorpromazine, cyproheptadine, dicyclomine, diphenhydramine,
fluphenazine, hydroxyzine, hyoscyamine, imipramine, oxybutinin, meclizine, perphenazine, promethazine, thioridazine, thiothixene,
tizanidine, trifluoperazine
Anticholinergic Burden and Cognitive and Functional Status 105
anticholinergic drug use and BI were adjusted for age, sex and
CIRS severity index. In view of non-normality in SBT and BI
scores, the models were also evaluated using logistic regres-
sions with SBT and BI cut point intervals as response vari-
ables, obtaining the significance reported in Tables 2, 3, 4, 5.
The Pearson correlation coefficient of the univariate model
was used to study the association between the change in the BI
score and change in ACB or ARS scores. Analyses were done
with JMP Pro 9 (SAS Institute Inc., Cary, NC, USA).
3 Results
3.1 Anticholinergic Drug Exposure According
to the Anticholinergic Cognitive Burden (ACB)
Scale and Anticholinergic Risk Scale (ARS)
Sixty-six internal medicine and geriatric wards participated
in the REPOSI study and recruited 1,380 patients. Of these,
1,232 had SBT scores between 0 and 24 and were included.
According to the ACB scale and ARS, respectively, 724
(58.8 %) and 112 (9.1 %) patients received at least one
anticholinergic drug. Table 6 summarizes their sociode-
mographic characteristics. The most commonly prescribed
anticholinergic medications (Table 7) are those with pos-
sible anticholinergic effects but no known clinically rele-
vant cognitive effects according to the ACB scale (score of
1) or with a low risk of anticholinergic adverse effects
according to the ARS (score of 1). Multivariate analysis,
adjusted for age, sex and CIRS severity index found no
differences in length of hospital stay between anticholin-
ergic non-users (mean 10.6 days; 95 % CI 9.9–11.3) and
anticholinergic drug users (mean 10.9 days; 95 % CI
10.3–11.5; p = 0.56) according to the ACB scale. Similar
results were found with the ARS between anticholinergic
non-users (mean 10.8 days; 95 % CI 10.3–11.2) and anti-
cholinergic drug users (mean 10.7 days; 95 % CI 9.2–12.2;
p = 0.92). No association between the length of stay and
the anticholinergic burden was found when the total score
of the ACB scale or ARS was used as a continuous variable
(slope = 0.04, p = 0.86, for ACB scale; slope = 0.10,
p = 0.82, for ARS).
Table 2 Association between Short Blessed Test (SBT)a and anticholinergic drug use in patients with SBT scores of 0–24
Analysis Any anticholinergic drug according to ACB scale Any anticholinergic drug according to ARS
Use (n = 724) Non-use (n = 508) p value Use (n = 112) Non-use (n = 1,120) p value
Univariate analysis
Median (IQR) 8 (3–14) 6 (2–12) 10 (4–14) 8 (2–13)
Mean (95 % CI) 8.9 (8.4–9.4) 7.8 (7.2–8.4) 0.006 9.7 (8.4–10.9) 8.3 (7.9–8.7) 0.04
Analysis adjusted for age, sex,
education, mean number of
drugs,b stroke and TIA
9.2 (8.6–9.9) 8.5 (7.8–9.2) 0.05 9.9 (8.7–11.2) 8.8 (8.2–9.4) 0.07
ACB Anticholinergic Cognitive Burden, ARS Anticholinergic Risk Scale, CI confidence interval, IQR interquartile range, TIA transient ischaemic
attack
a Higher scores indicate worse cognition
b Excluding anticholinergic drugs
Table 3 Dose–response relationship in models adjusted for age, education, mean number of drugs,a stroke and transient ischaemic attack
ACB scale and SBT scores ARS and SBT scores
Sum of ACB scale scores Patients (n) SBTb [mean (95 % CI)] Sum of ARS scores Patients (n) SBTb [mean (95 % CI)]
0 508 8.5 (7.8–9.2) 0 1,120 8.8 (8.2–9.4)
1 407 9.1 (8.3–9.9) 1 73 10.3 (8.8–11.8)
2 200 9.3 (8.3–10.2) 2 23 8.7 (6.1–11.3)
3 80 9.5 (7.9–11.0) C3 16 9.8 (6.6–13.1)
4 23 9.4 (6.8–12.1)
C5 14 10.6 (7.3–13.9)
ACB Anticholinergic Cognitive Burden, ARS Anticholinergic Risk Scale, CI confidence interval, SBT Short Blessed Test
a Excluding anticholinergic drugs
b Higher scores indicate worse cognition
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3.2 Relationship between Anticholinergic Burden
and Short Blessed Test (SBT)
3.2.1 ACB Scale and SBT
The SBT was available for 1,232 patients. According to the
ACB scale, 724 patients were treated with at least one
anticholinergic drug (Tables 2 and 3). In the univariate
model, the mean SBT score of patients treated with
anticholinergic drugs (8.9; 95 % CI 8.4–9.4) was about one
point higher than that of patients without any anticho-
linergic medications (7.8; 95 % CI 7.2–8.4; p = 0.006).
The difference was similar after adjustment for age, sex,
education, and history of stroke or TIA. The mean SBT
score of patients treated with anticholinergic drugs (9.2;
95 % CI 8.6–9.9) was significantly higher than the score
(8.5; 95 % CI 7.8–9.2) for patients without anticholinergic
drugs (p = 0.05). A dose–response relationship was
Table 4 Association between Barthel Indexa during hospital stay and anticholinergic drug use in patients with Short Blessed Test (SBT) scores
of 0–24
Analysis Any anticholinergic drug according to ACB scale Any anticholinergic drug according to ARS
Use (n = 681) Non-use (n = 487) p value Use (n = 102) Non-use (n = 1,066) p value
Univariate analysis
Median (IQR) 92 (73–100) 98 (85–100) 85 (62.5–100) 95 (80–100)
Mean (95 % CI) 82.4 (80.8–84.0) 87.8 (85.9–89.7) \0.0001 77.5 (73.3–81.6) 85.4 (84.1–86.7) 0.0004
Analysis adjusted for age,
sex and CIRS severity index
83.5 (81.9–85.0) 86.3 (84.4–88.1) 0.03 79.0 (74.9–83.0) 85.2 (84.0–86.4) 0.006
ACB Anticholinergic Cognitive Burden, ARS Anticholinergic Risk Scale, CI confidence interval, CIRS Cumulative Illness Rating Scale, IQR
interquartile range
a Higher scores indicate less impairment
Table 5 Dose–response
relationship in models adjusted
for age, education, mean
number of drugs, stroke and
transient ischaemic attack
ACB Anticholinergic Cognitive
Burden, ARS Anticholinergic
Risk Scale, BI Barthel Index, CI
confidence interval
a Higher scores indicate less
impairment
ACB scale and BI scores ARS and BI scores
Sum of ACB
scale scores
Patients
(n)
BIa
[mean (95 % CI)]
Sum of ARS
scores
Patients
(n)
BIa
[mean (95 % CI)]
0 487 86.3 (84.4–88.1) 0 1,066 85.2 (84.0–86.4)
1 382 83.0 (81.0–85.1) 1 67 81.4 (76.4–86.4)
2 190 83.9 (80.9–86.8) 2 20 77.8 (68.7–86.8)
3 73 85.7 (80.9–90.4) C3 15 71.5 (61.1–81.9)
4 22 85.5 (76.9–94.2)
C5 14 77.3 (66.4–88.2)
Table 6 Sociodemographic characteristics of patients with Short Blessed Test scores of 0–24 according to anticholinergic drug use at admission
Characteristic ACB scale ARS
Use Non-use p value Use Non-use p value
Number of patients 724 508 112 1,120
Age (years; mean ± SD) 79.0 ± 7.3 78.0 ± 7.0 0.02 79.1 ± 7.2 78.5 ± 7.2 0.42
Female (%) 50.3 47.2 0.29 58.0 48.1 0.05
Number of drugsa (mean ± SD) 4.9 ± 2.4 3.7 ± 2.2 \0.0001 5.5 ± 2.7 5.2 ± 2.8 0.33
Education (years; mean ± SD) 7.1 ± 4.1 7.4 ± 4.2 0.22 7.3 ± 4.2 7.2 ± 4.1 0.85
CIRS
Diagnosis (n; mean ± SD) 6.3 ± 2.8 4.9 ± 2.5 \0.0001 6.5 ± 3.0 5.6 ± 2.7 0.006
Severity index score (mean ± SD) 1.7 ± 0.3 1.5 ± 0.3 \0.0001 1.7 ± 0.3 1.6 ± 0.3 0.02
Comorbidity index score (mean ± SD) 3.2 ± 1.7 2.4 ± 1.6 \0.0001 3.4 ± 1.8 2.8 ± 1.7 0.002
ACB Anticholinergic Cognitive Burden, ARS Anticholinergic Risk Scale, CIRS Cumulative Illness Rating Scale
a Excluding anticholinergic drugs
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observed between higher total ACB score and cognitive
impairment; patients who scored 1 had a 0.6-point decline
in SBT scores. A plateau effect was found in patients who
scored 2–4, with 0.8-, 0.9- and 1.0-point declines, respec-
tively; patients who scored 5 or more had about a 2.1-point
greater decline than those not taking anticholinergic drugs.
Results of the univariate and multivariate analyses were
similar after inclusion of 13 demented patients (previously
excluded for the diagnosis of dementia or treatment with
anticholinesterase agents or memantine). In the multivari-
ate model, the mean SBT score for patients treated with
anticholinergic drugs (9.4; 95 % CI 8.7–10.1) was higher
than the mean score (8.7; 95 % CI 8.0–9.4) for patients
without anticholinergic drugs (p = 0.07), although the
difference was only marginally significant. The dose–
response relationship was maintained.
3.2.2 ARS and SBT
The ARS identified 112 patients receiving at least one
anticholinergic drug. In the univariate model, the mean
SBT score of patients treated with anticholinergic drugs
(9.7; 95 % CI 8.4–10.9) was 1.4 points higher than that of
patients receiving no anticholinergic medication (8.3; 95
% CI 7.9–8.7; p = 0.04). In the multivariate model, after
adjustment for age, sex education, stroke and TIA, the
difference was only marginally significant (Tables 2 and 3)
and there was no dose–response relationship between
higher total ARS score and cognitive decline. Results were
similar after inclusion of 13 demented patients; in the
multivariate analysis, the mean SBT score for patients
treated with anticholinergic drugs (9.8; 95 % CI 8.5–11.0)
was higher than the mean score (8.4; 95 % CI 8.0–8.8) for
patients without anticholinergic drugs (p = 0.05).
The results of univariate and multivariate analyses after
exclusion of patients with a diagnosis of delirium (n = 8)
at hospital admission did not differ for both the ACB scale
and ARS.
3.3 Relationship between Anticholinergic Burden
and Barthel Index (BI)
3.3.1 ACB Scale and BI
Out of the 1,245 patients in the analysis of the association
between drug-related anticholinergic burden and SBT, the
BI was available for 1,167 at admission. In the univariate
analysis, the use of anticholinergic drugs was associated
with greater impairment in basic activities of daily living
(Tables 4 and 5). The mean BI score of patients treated
with anticholinergic drugs (82.4; 95 % CI 80.8–84.0) was
about 5 points lower than that of patients receiving no
anticholinergic medication (87.8; 95 % CI 85.9–89.7;
p \ 0.0001). The independent association between cumu-
lative anticholinergic exposure and poorer BI rating was
maintained after adjustment for age, sex and CIRS severity
index, the mean BI score for patients treated with anti-
cholinergic drugs being 83.5 (95 % CI 81.9–85.0) as
opposed to 86.3 (95 % CI 84.4–88.1; p = 0.03) for those
not treated with these drugs. No dose–response relationship
was been observed.
BI scores were available for 666 patients at the 3-month
follow-up; the mean BI score adjusted for age, sex and
CIRS severity index was 82.8 (95 % CI 80.7–84.9) in
anticholinergic drug users and 86.7 (95 % CI 84.2–89.2) in
non-users (p = 0.02). Analysis of the dose–response rela-
tionship confirmed that patients who scored 4 or more had
a higher degree of impairment (mean BI score 80.7; 95 %
CI 72.5–89.0; p \ 0.0001).
3.3.2 ARS and BI
The ARS identified 102 patients with at least one anti-
cholinergic drug and a BI rating. The mean BI score at
admission was significantly lower for patients using anti-
cholinergic medications in both univariate and multivariate
models. After adjustment for age, sex and CIRS severity
index, the mean BI scores were 79.0 (95 % CI 74.9–83.0)
Table 7 Anticholinergic medications most commonly prescribed
according to the Anticholinergic Cognitive Burden (ACB) Scale and
Anticholinergic Risk Scale (ARS)
Scale Drug Score Anticholinergic
users (n)
ACB scale Furosemide 1 439
Warfarin 1 143
Digoxin 1 98
Prednisone 1 63
Isosorbide 1 52
Atenolol 1 44
Metoprolol 1 37
Triamterene 1 26
Alprazolam 1 25
Nifedipine 1 24
ARS Carbidopa – levodopa 1 27
Ranitidine 1 26
Paroxetine 1 17
Quetiapine 1 9
Haloperidol 1 8
Pramipexole 1 8
Amitriptyline 3 7
Pseudoephedrine 2 4
Cetirizine 2 3
Olanzapine 2 2
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in anticholinergic drug users and 85.2 (95 % CI 84.0–86.4)
in non-users (p = 0.006) (Tables 4 and 5). A dose–
response relationship was observed between higher total
ARS score and ability in basic activities of daily living.
The association was confirmed at follow-up. In the multi-
variate model, the mean BI score was 76.9 (95 % CI
71.8–82.1) in anticholinergic drug users and 85.2 (95 % CI
83.5–86.9) in non-users (p = 0.003). A dose–response
relationship was also observed, the mean BI score of
patients who scored 3 or more being 68.7 (95 % CI
56.4–81.0; p \ 0.0001).
No correlation between change in anticholinergic
burden and change in BI score at 3 months after hospital
admission was found (correlation = 0.004, p = 0.91, for
ACB scale; correlation = -0.06, p = 0.15, for ARS).
3.4 Relationship between ACB Scale and ARS
Our results suggest that the ARS could be more specific but
less selective than the ACB scale in identifying patients
with a higher degree of cognitive impairment (Table 8).
Patients identified as not receiving anticholinergic drugs in
both scales were those with better cognitive performance
and ability in basic activities of daily living, while patients
identified only in the ARS had higher levels of cognitive
and physical impairment, although anticholinergic burden
was relatively low; one patient scored 3, four scored 2 and
16 scored 1. Neither the ACB scale nor the ARS were
associated with longer hospital stay.
4 Discussion
Consistent with our primary hypothesis, the cumulative
effects of anticholinergic drugs, as assessed by both the
ACB scale and ARS, were associated with cognitive and
functional impairment in a sample of elderly patients. The
ACB scale was more selective in capturing medications
with modest or in vitro antimuscarinic activity likely to
affect cognitive and physical performance, while the ARS
was more specific in capturing medication associated with
a higher degree of cognitive and functional of impairment.
No study has previously compared these two anticholin-
ergic scales. A recent, large, population-based study on
anticholinergic drugs using the ACB scale found an
increasing risk for cognitive decline (as measured by the
Mini-Mental State Examination) and mortality over
2 years in patients with normal or mildly impaired cogni-
tion [42]. It has also been postulated that patients with
Alzheimer’s disease (AD) may be at particular risk of
cognitive deterioration with the use of medications with
anticholinergic effects, because of the marked reduction in
the functioning of central cholinergic pathways [19, 43].
However, a recent study did not confirm this, concluding
that in patients with AD, medications with anticholinergic
effect according to the ACB scale did not affect deterio-
ration in cognition over the subsequent 18 months, thus not
supporting a continuous effect of these medications on
patients with AD [44].
The ARS score has also been associated with the risk of
central and peripheral anticholinergic adverse effects in
elderly patients. However, there are some differences
between the ACB scale and ARS: their lists of medications
with anticholinergic activity include a different number of
drugs and score some drugs differently. Furosemide, war-
farin and digoxin are not included in the ARS; paroxetine
and quetiapine are classified differently; they are considered
drugs with definite, clinically relevant anticholinergic
effects in the ACB scale (score of 3), while the ARS assigns
them a low risk of anticholinergic effects (score of 1).
In the present study, both the ACB scale and ARS iden-
tified patients with greater cognitive impairment among
those with no clinical diagnosis of dementia. According to
the ACB scale, the most prescribed anticholinergic drugs are
those with only serum anticholinergic activity or in vitro
affinity for muscarinic receptors with no clinically relevant
cognitive effects. This list includes furosemide, warfarin,
digoxin, prednisone and isosorbide. However, the
Table 8 Patients treated with
anticholinergic drugs according
to Anticholinergic Cognitive
Burden (ACB) Scale and
Anticholinergic Risk Scale
(ARS)
BI Barthel Index, CI confidence
interval, SBT Short Blessed Test
Anticholinergic use
Non-use in ACB
scale and ARS
Use only in
ACB scale
Use in ACB
scale and ARS
Use only
in ARS
Association with SBT
Number of patients 487 633 91 21
SBT score [mean
(95 % CI)]
7.7 (7.1–8.2) 8.9 (8.3–9.4) 9.2 (7.8–10.7) 11.6 (7.8–15.5)
Association with BI
Number of patients 484 631 91 21
BI score [mean
(95 % CI)]
85.8 (83.7–88.0) 78.8 (76.6–80.1) 73.0 (66.7–79.4) 62.8 (47.4–78.1)
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cumulative anticholinergic effects of these drugs have been
associated with greater cognitive impairment and a dose–
response relationship; according to our results patients who
scored 5 or more had a 2-point cognitive decline according to
the SBT. The clinical significance of a 2-point difference is
difficult to clarify because the rate of decline is generally
determined by the severity of dementia; the less severe the
dementia, the slower the rate of decline. The annual rate of
decline on the SBT is about 3.8 points in patients with
probable AD [48], and a 2-point difference could be compare
to a 6-month decline in patients with probable AD. In any
case, people receiving drugs with a combined ACB scale
score of 5 were found to have higher cognitive impairment
than those who took none of these drugs. This would be
enough to impair concentration and driving ability and,
additionally, in someone already experiencing cognitive
impairment, worsen memory problems, personality changes
or depression [49].
For many drugs with important clinical indications, such
as warfarin or digoxin, it is hard to suggest non-anticho-
linergic alternative drugs and it may be difficult to reduce
the anticholinergic burden. However, when there are
alternative drug choices, every attempt should be made to
avoid increasing a patient’s anticholinergic burden. An
association was also observed between drug-related anti-
cholinergic burden and impairment in basic activities of
daily living, although no dose–response relationship was
found, but patients who scored 5 or more had greater
physical impairment. In the ARS, no dose–response rela-
tionship with cognitive impairment was found, while there
was a clear relationship with the BI scale, suggesting that
the ARS should be the preferred scale for identifying
patients at higher risk of physical impairment.
Delirium is an acute cognitive failure and its relation-
ship with anticholinergic medication has been debated [50,
51]. In order to avoid the cognitive impairment related to
delirium, the SBT was conducted within 2 days of hospital
admission or after the patient stabilized. Analysis repeated
after inclusion of patients with a diagnosis of delirium gave
similar results for the ACB scale and ARS.
A limitation of this study is the lack of information on
the SBT at follow-up, because changes in a patient’s drug
regimen may have far-reaching effects on their anticho-
linergic burden. To date, no clinical trial has evaluated the
cognitive outcome of reducing anticholinergic burden, and
the lack of information on the SBT at follow-up excluded
the possibility of assessing the relationship between lon-
gitudinal cumulative anticholinergic exposure and cogni-
tive performance. We also did not examine the effects of
different doses. Another limitation of the study is that the
association between anticholinergic burden and cognitive
or functional outcome was a hypothesis: sicker patients
(with more cognitive or functional impairment) could be
more likely to be prescribed an anticholinergic medication.
However, biological, rational [19] and other observational
studies [22–25, 42] support the hypothesis that the cumu-
lative effects of anticholinergic drugs are associated with
cognitive and functional impairment. For the association
between anticholinergic drug use and cognitive impair-
ment, we adjusted analyses for possible confounders such
as age, sex, education, and history of stroke or TIA and
number of non-anticholinergic drugs, and, similarly, for the
association between anticholinergic drug use and physical
impairment, we adjusted for age, sex and CIRS severity
index, thus, limiting the potential bias of confounding by
indication. Another limitation is that the REPOSI study
was not designed to specifically collect the diagnosis of
dementia; we focused on patients with SBT scores of 0–24
in order to avoid the ceiling effects of this scale, thus,
excluding the majority of demented patients. The distri-
bution of patients with a diagnosis of dementia showed that
53 % had SBT scores between 25 and 28. However, some
patients with a diagnosis of dementia may have been
included.
5 Conclusions
Prescribers need to be vigilant for adverse anticholinergic
effects, particularly in older patients. The effects of anti-
cholinergic drugs on cognitive and physical performance
might be due to the cumulative effect of multiple medi-
cations with modest antimuscarinic activity. Different sets
of explicit criteria for potentially inappropriate medication,
such as the Beers [45] or Screening Tool to Alert Doctors
to Right Treatment/Screening Tool of Older Person’s
Prescriptions (START/STOPP) criteria [46], have been
developed to reduce the use of drugs that have no clear
evidence-based indication or that involve a substantial risk
of adverse effects in elderly patients [47]. Evaluation of
anticholinergic burden should be considered an additional
important strategy for optimizing polypharmacy, and the
incorporation of these scales into computer-assisted order
entry systems would facilitate evaluation of the anticho-
linergic burden in daily practice. According to the results
of this study, the ACB scale might help rapidly identify
drugs potentially associated with cognitive impairment
with a dose–response pattern, while the ARS seems better
used for identifying patients with impairment in activities
of daily living.
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